Rationale for Bisphosphonate use inpatients with endoprosthesis;Zasadność podawania bisfosfonianów pacjentom po endoprotezoplastykach stawów

Ortopedia Traumatologia Rehabilitacja

Volumn 8, Issue 2, 2006, Pages 226-231

  Jabłoński, Mirosław ^a   Gorzelak, Mieczysław ^a   Turzańska, Karolina ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Aseptic loosening; Bone atrophy; Wear debris

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; METAL;

ENDOPROSTHESIS; HUMAN; IMPLANT; JOINT PROSTHESIS; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; POSTTRAUMATIC OSTEOPOROSIS; REVIEW;

EID: 38549176187     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kozak J, Gorzelak M, Jabłoński M, Warda E, Bednarek A. Wpływ miejscowych i ogólnych czynników na trwałość wynikoẃ endoprotezoplastyk (patomorfizm stawu biodrowego, osteoporoza, błȩdy geometrii protezowanych bioder, zużycie nośnych elementów endoprotezy). W: Kozak J, Modrzewski K. Obluzowania aseptyczne w endoprotezoplastykach stawu biodrowego. Materiały naukowe Sympozjum, Lublin 1993. 23-29.
2. Engh CA, McGroven MS, Schmidt LM. Roentgenographic densitometry of bone adjacent to a femoral prosthesis. Clin Orthop Relat Res 1993; 292: 177-190.
3. Kusz D, Kaleta M, Bożek M, Służałek M. Zastosowanie badania densytometrycznego w ocenie endoprotezoplastyki bezcementowej stawu biodrowego. Chir Narz Ruchu Ortop Pol 1996; LXI (1): 169-175.
4. Blaine TA, Pollice PF, Rosier RN, Puzas JE, Looney RJ, Reynolds PR, Reynolds SD, O'Keefe RJ. Increased levels of tumor necrosis factor and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles. J. Bone Joint Surg 1996; 78-A: 1181-1192.
5. Watkins SC, Macaulay W, Turner D, Kang R, Rubash HE, Evans CH. Identification of inducible nitric oxide synthase in human macrophages surrounding loosened hip prostheses. Am J Path 1997; 150 (4): 1199-1206.
6. Ohlin A, Johnell O, Lerner UH. The pathogenesis of loosening of total hip arthroplasties. The production of factors by periprosthetic tissue that stimulate in vitro bone resorption. Clin Orthop 1990; 253: 287-296.
7. Ishiguro N, Ito T, Kurokouchi K, Iwahori Y, Nagaya I, Hasegawa Y, Iwata H. mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in interface tissue around implants in loosening total hip arthroplasty. J. Biomed Mater Res 1996; 32: 611-617.
8. Maloney WJ, Smith RL. Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. J Bone Joint Surg 1995; 77-A: 1448-1461.
9. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. J Bone Joint Surg 1997; 79-A: 1519-1528.
10. Hirakawa K, Bauer TW, Stulberg BN, Wilde AH, Secic M. Characterization and comparison of wear debris from failed total hip implants of different types. J. Bone Joint Surg 1996; 78-A: 1235-1243.
11. Haara MM, Arokoski JP, Kröger H, Karkkainen A, Manninen P, Knekt P, Impivaara O, Heliovaara M. Association of radiological hand osteoarthritis with bone mineral mass: a population study. Rheum Oxf 2005; 44 (12): 1549-54.
12. Frost HM. Dynamics of bone remodeling. W: Frost HM. Bone Biodynamic. Boston: Little, Brown; 1964. str. 315-333.
13. Raisz LG. Local and systemie factors In the pathogenesis of osteoporosis. N Engl J Med 1988; 318: 818-825.
14. Mundy RG. Bone resorbing Wells. W: Murray JF. Primer on the metabolic bone diseases and disorders of mineral metabolism. I wyd. Kelseyville: California American Society For Bone and Mineral Research; 1990 s18-22.
15. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269-280.
16. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russel RGG, Rodan GA, Reszka AA. Alendronate mechanism of action: gernylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoblast formation, bone resorption, and kinase resorption in vitro. Proc Natl Acad Sci USA 1999; 96: 133-138.
17. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
18. Firth JC, Mökkönen J, Blackburn GM, Russel RGG, Rogers MJ. Clonodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′ (β,?-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1997; 12: 1358-1367.
19. Kabayashi A, Hirano F, Makino I. The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheum 2005; 34 (6): 480-4.
20. Dobnig H, Kofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleiter-Pammer A. Changes in RANK ligand/osteoprotegrin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patient. Osteoporosis Int 2006; 25: 1-11.
21. Zerahn B, Storgaard M, Johansen T, Olsen C, Lausten G, Kanstrup IL. Changes in bone mineral density adjacent to two biomechanically different types of cementless femoral stems in total hip arthroplasty. Int Orthop 1998; 22: 225-229.
22. Kusz D. Porównawcza ocena zmian mineralnych w kosci udowej po endoprotezoplastyce cementowej stawu biodrowego typu Weiler i Centrament. Chir Narz Ruch Ortop Pol 1999; 64 (4): 407-414.
23. Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, Schunemann H, Einhorn TA. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg 2005; 87-A: 293-301.
24. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, Goldberg MJ, Harris WH. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg 1993; 75-A: 863-879.
25. Chiba J, Rubash HE, Kim KJ, Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res 1994; 300: 304-312.
26. Gil-Albarova J, Lacleriga A, Barrios C, Canadell J. Lymphocyte response to polymethylmethacrylate in loose total hip prostheses. J Bone Joint Surg 1992; 74-B: 825-830.
27. Shanbhag AS, Hasselman CT, Rubash HE. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res 1997; 344: 33-43.
28. Millet PJ, Allen MJ, Bostrom MP. Effects of aledronate on participle-induced osteolysis in a rat model. J Bone Joint Surg 2002; 84-A: 236-49.
29. O'Hara LI, Nivbrant B. Cross-linked polyethylene and bisphosphonate therapy for osteolysis in total hip arthroplasty: A case report. J Orthop Surg 2004; 12: 114-121.
30. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Mayer JM. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of BRISK randomized controlled trial [ISRCTNO 1928173]. Artr Res Ther 2005; 7: R625-R633.
31. von Konch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. Effects of bisphosphonates on proliferation and osteoblast differention of human bone marrow stromal cells. Biomaterials 2005; 26: 6941-6949.
32. Im G, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004; 25: 4105-4115.
33. Mochida Y, Bauer TW, Akisue T, Brown PR. Alendronate does not inhibit early bone apposition to hydroxyapatite-coated total joint implants: a preliminary study. J Bone Surg Am 2002; 84: 226-35.
34. Sivak MG, REnou SJ, Mandalunis PM, Guglielmotti MB. Olpadronate in peri-implant bone healing. An experimental study. Bone 2006; 38: 3 suppl. 1 B 116.
35. Tanzer M, Karabasz D, Krygier JJ, Cohen R, Boby JD. The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Rel Res 2005; 441: 30-9.
36. Tägil M, Astrand J, Westman L, Aspenberg P. Alendronate prwvents collapse in mechanically loaded osteochondral grafts. A bone chamber study in rats. Acta Orthop Skand 2004; 75 (6): 756-761.
37. Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kröger PJ. Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tiss 2002; 71 (6): 472-7.
38. Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Chen HS. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am 2003; 85: 21216.
39. Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastel R. Effects of Pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 2001; 16: 556-64.
40. Wilkinson JM,, Hamer AJ, Rogers A, Stockley I, Eastell R. Bone mineral density and biochemical markers of bone turnover in aseptic loosening after total hip arthroplasty. J Orthop Res 2003; 21: 691-6.